BC
FDMT icon

Birchview Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Birchview Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$645K Buy
+48,505
New +$473K 0.3% 48

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Birchview Capital's FDMT Position: Q2 2026 in Review

Birchview Capital opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 48,505 shares worth $645K. The stake represents 0.3% of the portfolio and ranks #48 among its holdings.

158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Birchview Capital held 48,505 shares of 4D Molecular Therapeutics worth $645K as of Q2 2026.
  • 4D Molecular Therapeutics was a new Birchview Capital position in Q2 2026.
  • 4D Molecular Therapeutics made up 0.3% of Birchview Capital's portfolio in Q2 2026, its #48 holding.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.